Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart


Date Filing Description Download
12/23/11 4 Statement of Changes in Beneficial Ownership
12/21/11 8-K Current report filing
12/19/11 3 Initial Statement of Beneficial Ownership
12/07/11 8-K Current report filing

Stock Quote

ACOR (Common Stock) $ 18.63 -0.18 (-0.96%) Volume: 686,131 MORE December 7, 2018

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *

Enter the code shown above.